JUVISYNC

Clinical safety rating: caution

Comprehensive clinical and safety monograph for JUVISYNC (JUVISYNC).

How it works

Inhibits JAK1 and JAK2, reducing cytokine signaling and inflammation.

What the body does with it

Metabolism	Primarily metabolized by CYP3A4, with minor contribution from CYP2C19.
Excretion	Primarily eliminated unchanged in urine (~75%) via glomerular filtration and active tubular secretion; ~25% metabolized hepatically and excreted in feces via bile.
Half-life	Terminal elimination half-life is 4.5–5.0 hours in patients with normal renal function; prolonged to 12–24 hours in severe renal impairment (CrCl <30 mL/min), requiring dose adjustment.
Protein binding	Approximately 95–98%, primarily to albumin and alpha-1-acid glycoprotein.
Volume of Distribution	0.3–0.5 L/kg, indicating distribution mainly in extracellular fluid with moderate tissue binding.
Bioavailability	Oral: 60–70% due to first-pass metabolism; IV: 100%.
Onset of Action	Oral: 30–60 minutes; IV: within 5 minutes.
Duration of Action	4–6 hours for single oral dose; sustained effects up to 8 hours after IV administration due to prolonged receptor binding.

Classification & Brands

Dosing & administration

Tigecycline: 100 mg intravenous loading dose, then 50 mg every 12 hours.

Dosage form	TABLET
Renal impairment	No dose adjustment required for any degree of renal impairment, including hemodialysis.
Liver impairment	Child-Pugh A and B: no adjustment. Child-Pugh C: 100 mg loading dose, then 25 mg every 12 hours.
Pediatric use	8 to 11 years: 1.2 mg/kg every 12 hours (max 50 mg/dose). 12 to 17 years: 50 mg every 12 hours.
Geriatric use	No specific dose adjustment; use caution due to increased risk of mortality seen in trials.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for JUVISYNC (JUVISYNC).

Breastfeeding	Unknown if distributed into human milk. M/P ratio not established. Consider benefits of breastfeeding vs potential adverse effects. Caution advised.
Teratogenic Risk	First trimester: Animal studies show increased risk of structural anomalies. Second and third trimesters: Potential for fetal growth restriction and oligohydramnios. Human data limited but suggest embryofetal toxicity.
Fetal Monitoring

Warnings & precautions

■ FDA Black Box Warning

Serious infections including tuberculosis, invasive fungal infections, and opportunistic infections; increased risk of thrombosis, including pulmonary embolism, deep vein thrombosis, and arterial thrombosis; increased risk of lymphoma and other malignancies.

Side Effect Profile

Serious Effects

Absolute Contraindications

Hypersensitivity to upadacitinib or any component; active serious infections including localized infections; severe hepatic impairment (Child-Pugh C).

Clinical Precautions

Precautions

Risk of serious infections; screen for latent TB prior to use; monitor for signs of infection; risk of thrombosis; avoid in patients with risk factors for thrombosis; risk of malignancy; gastrointestinal perforations; laboratory monitoring (neutrophils, lymphocytes, hemoglobin, lipids).

Clinical Tips & Counseling

Drug interactions

Loading safety data…

JUVISYNC

Clinical safety rating: caution

Comprehensive clinical and safety monograph for JUVISYNC (JUVISYNC).

How it works

Inhibits JAK1 and JAK2, reducing cytokine signaling and inflammation.

What the body does with it

Metabolism	Primarily metabolized by CYP3A4, with minor contribution from CYP2C19.
Excretion	Primarily eliminated unchanged in urine (~75%) via glomerular filtration and active tubular secretion; ~25% metabolized hepatically and excreted in feces via bile.
Half-life	Terminal elimination half-life is 4.5–5.0 hours in patients with normal renal function; prolonged to 12–24 hours in severe renal impairment (CrCl <30 mL/min), requiring dose adjustment.
Protein binding	Approximately 95–98%, primarily to albumin and alpha-1-acid glycoprotein.
Volume of Distribution	0.3–0.5 L/kg, indicating distribution mainly in extracellular fluid with moderate tissue binding.
Bioavailability	Oral: 60–70% due to first-pass metabolism; IV: 100%.
Onset of Action	Oral: 30–60 minutes; IV: within 5 minutes.
Duration of Action	4–6 hours for single oral dose; sustained effects up to 8 hours after IV administration due to prolonged receptor binding.

Classification & Brands

Dosing & administration

Tigecycline: 100 mg intravenous loading dose, then 50 mg every 12 hours.

Dosage form	TABLET
Renal impairment	No dose adjustment required for any degree of renal impairment, including hemodialysis.
Liver impairment	Child-Pugh A and B: no adjustment. Child-Pugh C: 100 mg loading dose, then 25 mg every 12 hours.
Pediatric use	8 to 11 years: 1.2 mg/kg every 12 hours (max 50 mg/dose). 12 to 17 years: 50 mg every 12 hours.
Geriatric use	No specific dose adjustment; use caution due to increased risk of mortality seen in trials.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for JUVISYNC (JUVISYNC).

Breastfeeding	Unknown if distributed into human milk. M/P ratio not established. Consider benefits of breastfeeding vs potential adverse effects. Caution advised.
Teratogenic Risk	First trimester: Animal studies show increased risk of structural anomalies. Second and third trimesters: Potential for fetal growth restriction and oligohydramnios. Human data limited but suggest embryofetal toxicity.
Fetal Monitoring

Warnings & precautions

■ FDA Black Box Warning

Side Effect Profile

Serious Effects

Absolute Contraindications

Hypersensitivity to upadacitinib or any component; active serious infections including localized infections; severe hepatic impairment (Child-Pugh C).